Dipyridamole Assessment for Flare Reduction in SLE (systemic lupus erythematosus)

Trial Profile

Dipyridamole Assessment for Flare Reduction in SLE (systemic lupus erythematosus)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Aspirin
  • Indications Systemic lupus erythematosus
  • Focus Biomarker; Therapeutic Use
  • Acronyms DARE
  • Most Recent Events

    • 15 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2020.
    • 15 Sep 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 26 Sep 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top